化瘀丸联合化疗治疗晚期卵巢癌临床研究

Clinical Study on Huayu Pill Combined with Chemotherapeutic Regimes in Treating Epithelial Ovarian Cancer

目的观察化瘀丸联合TC方案化疗对晚期卵巢癌的疗效及化疗毒副反应。方法将60例晚期卵巢癌患者随机分为治疗组(化瘀丸联合TC方案化疗)30例、对照组(TC方案化疗)30例,观察2组血瘀证候症状分级量化积分、生活质量、化疗毒副反应、近期疗效以及血凝指标。结果2组有效率(CR+PR)分别为46.7%、37.9%(P>0.05),临床获益率(CR+PR+SD)分别为86.7%、68.9%(P<0.05);治疗组化疗前后卡氏评分未见明显下降,对照组化疗后显著下降;治疗组与对照组比较,肌肉关节痛轻微,纤维蛋白原、D-二聚体、血瘀证积分明显降低(P<0.05)。结论化瘀丸联合化疗可减低血液高凝状态,缓解化疗药物的毒副反应,提高患者的生活质量。

Objective To observe clinical effects and side reactions of Huayu pill combined with TC （Paclitaxel＋Carboplatin） chemotherapeutic regimes on treating epithelial ovarian cancer. Methods All 60 patients with the epithelial ovarian cancer were randomly divided into the treated group （Huayu pill combined with TC chemotherapeutic, n =30） and the control group （TC chemotherapeutic regimes, n =30） Results The effective rate of the treated group and the control group was 46.7% and 37.9% respectively. The objective response rate （CR＋PR＋SD） was 86.7% in the treated group, while this rate was 68.9% in the control group （P〈0.05）. Huayu pill can reduce the hypercoagulation of blood and side effects of chemical medicine and improve the quality of life. Conclusion Combined with TC chemotherapeutic regimes, Huayu pill can bring better clinical effects and relieve side effects of chemical medicine.